Orchestration of Tryptophan‐Kynurenine Pathway, Acute Decompensation, and Acute‐on‐Chronic Liver Failure in Cirrhosis. Issue 4 (19th March 2019)

• Record Type: Journal Article
• Authors: Clària, Joan; Moreau, Richard; Fenaille, François; Amorós, Alex; Junot, Christophe; Gronbaek, Henning; Coenraad, Minneke J.; Pruvost, Alain; Ghettas, Aurélie; Chu‐Van, Emeline; López‐Vicario, Cristina; Oettl, Karl; Caraceni, Paolo; Alessandria, Carlo; Trebicka, Jonel; Pavesi, Marco; Deulofeu, Carme; Albillos, Agustin; Gustot, Thierry; Welzel, Tania M.; Fernández, Javier; Stauber, Rudolf E.; Saliba, Faouzi; Butin, Noémie; Colsch, Benoit; Moreno, Christophe; Durand, François; Nevens, Frederik; Bañares, Rafael; Benten, Daniel; Ginès, Pere; Gerbes, Alexander; Jalan, Rajiv; Angeli, Paolo; Bernardi, Mauro; Arroyo, Vicente;
• Is Part Of: Hepatology. Volume 69:Issue 4(2019)
• Page Start: 1686
• Page End: 1701
• Publication Date: 2019-03-19
• Subjects: Heart -- Diseases -- Nursing -- Periodicals; Lungs -- Diseases -- Nursing -- Periodicals; Intensive care nursing -- Periodicals; Foie -- Maladies -- Périodiques; 616.362
• DOI: 10.1002/hep.30363
• Languages: English
• ISSNs: 0270-9139

Abstract

Abstract : Systemic inflammation (SI) is involved in the pathogenesis of acute decompensation (AD) and acute‐on‐chronic liver failure (ACLF) in cirrhosis. In other diseases, SI activates tryptophan (Trp) degradation through the kynurenine pathway (KP), giving rise to metabolites that contribute to multiorgan/system damage and immunosuppression. In the current study, we aimed to characterize the KP in patients with cirrhosis, in whom this pathway is poorly known. The serum levels of Trp, key KP metabolites (kynurenine and kynurenic and quinolinic acids), and cytokines (SI markers) were measured at enrollment in 40 healthy subjects, 39 patients with compensated cirrhosis, 342 with AD (no ACLF) and 180 with ACLF, and repeated in 258 patients during the 28‐day follow‐up. Urine KP metabolites were measured in 50 patients with ACLF. Serum KP activity was normal in compensated cirrhosis, increased in AD and further increased in ACLF, in parallel with SI; it was remarkably higher in ACLF with kidney failure than in ACLF without kidney failure in the absence of differences in urine KP activity and fractional excretion of KP metabolites. The short‐term course of AD and ACLF (worsening, improvement, stable) correlated closely with follow‐up changes in serum KP activity. Among patients with AD at enrollment, those with the highest baseline KP activity developed ACLF during follow‐up. Among patients who had ACLF at enrollment, those with immune suppression and the highest KP activity, both at baseline, developed nosocomial infections during follow‐up. Finally, higher baseline KP activity independently predicted mortality in patients with AD and ACLF. Conclusion: Features of KP activation appear in patients with AD, culminate in patients with ACLF, and may be involved in the pathogenesis of ACLF, clinical course, and mortality.